Loading stock data…
Praxis Precision Medicines (PRAX)
$350.56+22.77 (+6.95%)
After Hours$340.10-10.46 (-2.98%)· Last close Jun 29
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Praxis Precision Medicines, Inc. in the Healthcare sector is trading at $350.56 with a market capitalization of $7.2B. Wall Street consensus targets $619.78 (18 analysts), implying a +76.8% move over the next 12 months. The stock is currently near its 52-week high of $366.52, remaining 38.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +76.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$105.86M↓ | -$97.04M↓ | -$78.36M↓ | -$76.07M↓ | -$74.73M |
| Net Income | -$92.56M↓ | -$88.91M↓ | -$73.93M↓ | -$71.13M↓ | -$69.30M |
Peer Comparison
JNJUNHPFE
Fundamentals
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.19B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-23.16%
Volume
Today's trading volume
681,919
Recent News
Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designation
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) shares climbed 4% on Monday after the company announced that the U.
Praxis Precision Medicines (PRAX) Stock After Mixed POWER1 Trial Results How Does The Valuation Stack Up
POWER1 results reshape focus on vormatrigine and investor attention Praxis Precision Medicines (PRAX) is back in focus after mixed topline results from its Phase 2/3 POWER1 trial of vormatrigine in focal onset seizures, prompting a pause in the related POWER2 study. The trial did not meet its primary goal on seizure frequency, but hit a key 50% responder rate and showed stronger seizure reduction at the higher 30 mg dose, while maintaining a generally favorable safety profile. See our latest...
BTIG Reaffirms Buy Rating for Praxis Precision Medicines (PRAX)
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 best AI driven biotech stocks to invest in. On June 2, BTIG reduced the price target on Praxis Precision Medicines Inc. (NASDAQ:PRAX) from $843 to $810. The firm maintained a Buy rating on the stock, informing investors that although the company’s Phase 2/3 POWER1 trial […]
Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On June 2, Praxis Precision Medicines Inc. (NASDAQ:PRAX) published the findings of its extensive Phase 2/3 POWER1 study. This research evaluated the effectiveness of vormatrigine as a treatment for individuals with focal onset seizures. This study […]
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.